Single Domain Antibodies (Nanobodies) Targeting SARS-CoV-2 for treating COVID-19
Summary:
The NCI seeks licensing and/or co-development research collaborations for SARS-CoV-2 targeting nanobodies.
T-cell Phenotypes Associated with Clinical Response to Adoptive Immunotherapy
Summary:
The NCI seeks applications from parties interested in co-developing and/or licensing a method to develop improved cancer immunotherapies.
Immunogens for Use in a High Efficacy HIV Vaccine
Summary:
The Vaccine Branch is seeking statements of capability or interest from parties interested in licensing V1-deleted immunogens to further develop, evaluate, or commercialize an improved HIV vaccine.
Synergistic Use of Exo VII Inhibitors And Quinolone Antibiotics For Treating Bacterial Infection
Summary:
The NCI seeks co-development partners or licensees to further develop the novel ExoVII inhibitor(s) as antibiotic adjuvants for enhancing the efficacy of quinolone antibiotics, particularly in quinolone-resistant bacterial strains.
Automated Digital Pathology Device for High-Throughput Demand
Summary:
The NCI is seeking licensees to develop an automated digital pathology device compatible with high-throughput data analysis.
HIV-1 IN Mutant in a Single Round Vector
Summary:
The Retroviral Replication Laboratory of the National Cancer Institute actively seeks parties interested in non-exclusive licensing a collection of single-round vectors containing mutations in HIV-1 IN or RT.
Anti-Viral Polypeptide Griffithsin: Compounds, Compositions, and Methods of Use
Description of Technology:
This technology describes additional methods of using the griffithsin anti-viral polypeptides described in related NCI invention (reference number E-106-2003). Specifically, this invention describes the use of GRFT to inhibit viral infection of hepatitis C viral infection, a severe acute respiratory syndrome (SARS) viral infection, an H5N1 viral infection, or an Ebola viral infection.
Adjuvanted Mucosal Subunit Vaccines for Preventing SARS-CoV-2 Transmission and Infection
Summary:
Inventors are seeking licensing and/or co-development research collaborations for a unique novel molecular Adjuvanted Mucosal Subunit Vaccine to prevent SARS-CoV-2 transmission and infection.
Peptide Hydrogels for Rate-Controlled Delivery of Therapeutics
Description of Technology:
Hydrogels represent an attractive controlled drug-delivery system that have been used in various clinical applications, such as: tissue engineering for wound healing, surgical procedures, pain management, cardiology, and oncology. High-water content of hydrogels confers tissue-like physical properties and the crosslinked fibrillar network enables encapsulation of labile small molecule drugs, peptides, proteins, nucleic acids, proteins, nanoparticles, or cells.
RNASEH-Assisted Detection Assay for RNA
Summary:
The NCI seeks research co-development partners and/or licensees for the development and commercialization of a diagnostic assay that detects sequence-specific (viral) RNA.